FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL										
	OMB Number: 3235-02										
	Estimated average burden hours per response: 0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Pine Michael Craig				2. Issuer Name and Ticker or Trading Symbol EyePoint Pharmaceuticals, Inc. [EYPT]								(Ch	eck all appli Directo Y Officer	cable) or (give title	g Pers	10% Ow Other (s	vner	
(Last) (First) (Middle) 480 PLEASANT ST, STE A210				3. Date of Earliest Transaction (Month/Day/Year) 05/25/2023								below) Chief		v.&St	below)	er		
(Street)	POMINI I		02472	4. If <i>A</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)									vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person				
WATERTOWN MA 02472														Form filed by More than One Reporting Person				
(City) (State) (Zip)					Rul	Rule 10b5-1(c) Transaction Indication												
									icate that a tra defense cond						on or written	n plan ti	hat is intende	d to
		Tab				_			quired, D	isp								
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				Execution Date,			Code (Instr. 5)					Benefici	es ally Following	Form (D) or	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
							Code	v	Amount	ount (A) or (D)		Transac	Transaction(s) (Instr. 3 and 4)			(Instr. 4)		
		7							uired, Dis , options					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversior or Exercise Price of Derivative Security		3A. Deeme Execution I if any (Month/Day	Date, 1	4. Transaction Code (Instr. 8)		5. Numb of Derivati Securiti Acquire (A) or Dispose of (D) (Instr. 3, and 5)	ve es ed	6. Date Exer Expiration I (Month/Day/	ate		7. Title and Amount of Securities Underlying Derivative 9 (Instr. 3 and		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		piration te	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$5.93	05/25/2023			A		15,000		(1)	05/	/24/2033	Common Stock	15,000	\$0.00	15,000		D	
Restricted Stock Units	\$0.00	05/25/2023			A		7,500		(2)		(2)	Common Stock	7,500	\$0.00	7,500		D	

- 1. The option to purchase will vest and become exercisable as follows: 25% at May 25th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.
- 2. The restricted stock units will vest in three ratable annual installments beginning May 25, 2024.

Remarks:

/s/ Ron Honig, Attorney-in-05/30/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.